LSC - 2021 - Preclinical evaluation of IL-1ß inhibition against KRAS-mutant lung adenocarcinoma Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
Efficacy of osimertinib and histomolecular profile at progression in EGFR-mutated lung cancer Source: International Congress 2019 – Treatment of lung cancer Year: 2019
The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019
Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation Source: Eur Respir J 2002; 20: Suppl. 38, 270s Year: 2002
Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Source: Eur Respir J 2012; 39: 1437-1442 Year: 2012
Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004
Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006
Bronchoscopic intratumoural therapies for non-small cell lung cancer Source: Eur Respir Rev, 29 (156) 200028; 10.1183/16000617.0028-2020 Year: 2020
Clinical features of nonsmall cell lung cancer cases Source: Eur Respir J 2002; 20: Suppl. 38, 75s Year: 2002
Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017
An analysis of EGFR expression and tumour imaging in non-small cell carcinomas of lung Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
Comparison of clinic and pathological staging in non-small cell lung cancer Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010
Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
Features of N-staging in left-sided non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 719s Year: 2006
Immunohistochemical studies of COX-2, MMP-9, p53 and VEGF in non-small-cell lung cancer, specifically squamous cell carcinoma and adenocarcinoma Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012
Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011